cyrilzakka/clinical-trials huggingface dataset:
Big Data Analysis of the Use of bIomarkers Concentration

The investigators conducted a retrospective analysis of all measured concentrations performed in a large subset of laboratories located in the French Brittany from February 2010 the 17th to August 2015 the 30th, in adults over 20 years old.

The investigators are aimed at studying physicians' use and eventually misuse of biomarkers dosage and the characteristics of a broad population based on some biomarkers concentrations.

The rUBIDIuM study is a retrospective analysis that included all tests (but not including DNA analysis or HIV tests) performed in a large subset of laboratories located in the French Brittany from February 2010 the 17th to August 2015 the 30th. The area of study covers most of the Ille-et-Vilaine and a part of the Côtes d'Armor department in Brittany. The respective surface of these departments is 6775 and 6878 km2. All labs belong to the Biorance Laboratory group (consortium of 33 labs, Biorance Laboratoires Réunis) and are equipped with Roche Diagnostics instruments (Elecsys2010® analyzer, Roche diagnostics, Meylan, France).

The main objectives are to study physicians' use and eventually misuse of biomarkers dosage and the characteristics of this broad population based on some biomarkers concentrations.

For all adult patients \>20y that came to a participating lab during the study period, the investigators collected the following information: demographics data, data about the prescription (date of order, list of analysis recommended, the date of blood collection and analysis), about the prescribers and the results of the analyses. After a de-identifying process, data were aggregated.

the initial analyses will 1) examine the biological tests (number, types...) ordered in a large cohort of patients, in the total population and the subgroups based on gender, age, time period, kind of lab and physicians' specialty, 2) examine the results/concentration of the analyses: blood chemistry, creatinin concentration, cardiac enzymes, natriuretic peptides, INR, lipid profile, hemogram...

Eligibility Criteria:
Inclusion Criteria:

* All adult patients \>20 that came to a participating lab (Biorance Laboratoires Réunis) during the study period for biological measurement

Exclusion Criteria:

* DNA analysis, HIV test
Promoting Optimal Healing After Laceration Repair Study

The goal of this research is to investigate three different methods of perineal skin closure during second-degree perineal wound repair and determine which method is associated with the least amount of patient pain.

Null hypothesis: There will be no difference in patient pain among the three different methods for second degree perineal wound repair.

At the University of Michigan, there are currently two standard techniques for repairing second-degree perineal lacerations that differ only in management of the perineal skin :

1. Closure of the deep tissues and superficial perineal skin using a continuous 3-0 Vicryl suture
2. Closure of the deep tissues with a continuous 3-0 Vicryl suture and reapproximation of, but not suture-closure of the perineal skin.

The primary goal of our study is to compare patient pain amongst the following three perineal skin repair techniques after second degree laceration:

1. Perineal skin closure with suturing
2. Not suturing the perineal skin
3. Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue.

In all women, the deep vaginal and perineal tissues will be closed using a continuous 3-0 Vicryl suture, as is current standard practice.

Aim: To assess and compare patient pain among the three groups at intervals of 1 day, 2 weeks, 6 weeks and 3 months postpartum.

Eligibility Criteria:
Inclusion Criteria:

* Women 18 years old - 45 years old
* Immediately post-vaginal birth, including forceps-assisted vaginal delivery, vacuum-assisted vaginal delivery
* \> 32 weeks gestation
* Second degree laceration from spontaneous tear or midline episiotomy
* Proficient in English

Exclusion Criteria:

* \<18 years old and \>45 years old
* Delivery by Cesarean
* 1st, 3rd or 4th degree lacerations
* Induction for intrauterine fetal demise or terminal fetal condition, or any instance where immediate status of the newborn is unknown
* Known allergy to cyanoacrylate or formaldehyde
* Systemic infections, uncontrolled diabetes (women with well-controlled pre-gestational or gestational diabetes will not be excluded)
* History of connective tissue disorders (e.g. Scleroderma, Ehlers Danlos)
* Chronic use of steroids
* Currently under treatment for cancer
* Previous radiation to the pelvis
* Any organ transplants
* History of neurological conditions including multiple sclerosis, stroke, Alzheimer's, or other dementias
* Not proficient in the English language
Comparison of Flexible & Navigable Suction Ureteral Access Sheath vs. Antegrade Suction in Retrograde Flexible Ureteroscopy for Lower Calyceal Stones

This randomized controlled trial aims to compare the efficacy and safety of two suction techniques during retrograde flexible ureteroscopy (FURS) for lower calyceal renal stones measuring 1.5-2 cm. The study evaluates Flexible \& Navigable Suction Ureteral Access Sheath (FANS) versus Antegrade Suction (via percutaneous access) in improving stone-free rates (SFR), reducing operative time, and minimizing complications such as bleeding, ureteral injury, and infection. A total of 120 adult patients will be randomized into two groups, undergoing either flexible ureteroscopy (FURS) with Flexible \& Navigable Suction Ureteral Access Sheath (FANS) or flexible ureteroscopy (FURS) with antegrade suction, at Banha University Faculty of Medicine.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (≥18 years old)
* Patients diagnosed with renal stones (1.5-2 cm) confirmed by non-contrast computed tomography (NCCT)
* Patients undergoing flexible ureteroscopy (FURS) as the primary treatment approach
* Patients with no active urinary tract infection (UTI) at baseline
* Patients who provide written informed consent

Exclusion Criteria:

* Patients with anatomical anomalies (e.g., horseshoe kidney, PUJ obstruction)
* Patients with a single functioning kidney
* Pregnant women
* Patients with a history of urological malignancy
* Patients with active bleeding disorders or those on anticoagulant therapy that cannot be safely discontinued
* Patients at high risk for anesthesia
Therapeutic Exercise to Treat Neuropathic Pain

A quasi-experimental, prospective clinical trial with pre and post intervention measurements, whose porpuose is assess the efficacy of a therapeutic exercise protocol to treat neuropathic pain in Fabry Disease.

There take part in this study women or men aged between 18 and 65 years, with a diagnosys by a physician specializing in Fabry disease with FabryScan. Patients must present a stable evolution, with a scoring system of disease severity (DS3) that must be less than 8 points per year in the last 2-3 years and they have to presence of neuropathic pain with a score greater than or equal to 4 in the questionnaire "Douleur neuropathique (DN4)".

Eligibility Criteria:
Inclusion criteria:

* Female or male patients between 18 years and 65 years.
* Patients diagnosed by a doctor specializing in Fabry disease with FabryScan.
* Fabry's disease must have a stable evolution, with a disease severity scoring system (DS3) that must be less than 8 points per year in the last 2-3 years.
* Presence of neuropathic pain with a score greater than or equal to 4 in the "Douleur neuropathique (DN4)" questionnaire.

Exclusion criteria:

* Patients with an acute cardiovascular disease or with a heart or kidney transplant.
* Subjects with acute orthopedic problems that limit their participation in the study.
* Subjects with cognitive impairments that prevent them from filling in the questionnaires or understanding the exercises to be performed.
Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

The objectives of the study are to identify doses of PPM-204 that are therapeutically effective and well tolerated in improving glycemic control over 24 weeks of treatment in subjects with type 2 diabetes mellitus (T2DM).

Eligibility Criteria:
Inclusion Criteria:

* Men and women of non-childbearing potential, 18 to 70 years old
* Subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication
* BMI \> 23 and \< 43
* For subjects currently treated with 1 antidiabetic medication: HbA1c is greater than or equal to 6.8% and less than or equal to 8.5%.
* For subjects not currently treated with antidiabetic medications: HbA1c is greater than or equal to 7.2% and less than or equal to 9.0%

Exclusion Criteria:

* Subjects requiring insulin therapy
* Subjects currently receiving 2 or more oral antidiabetic medications
* Subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit
* Subjects receiving warfarin
* Subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit
* Significant diabetic complications (retinopathy, nephropathy, symptomatic neuropathy)
Developing an Objective Measure of Experienced Pain

Pain is a public health challenge around the world. However, there is no single standardized measure of pain, to the point that the estimated prevalence of chronic pain in adults ranges between 2% and 64% depending on the methods and definitions used. Existing measures of pain are known to present several problems and results can be hardly compared between people.

The investigators propose and empirically validate a new, simple method to measure experienced pain in clinical trials. The method provides an objective, cardinal measurement of experienced pain which is comparable between people and the investigators test whether it is better able to measure experienced pain than existing procedures. The investigators test the new method in healthy participants using standard protocols (electrical and heat stimuli). The investigators also aim to validate the measure using a causal manipulation which relies on the administration of a topical analgesic product compared to a placebo.

The aim of this study is to establish and validate the proposed method of measuring pain using different pain stimuli. The investigators correlate these measurements with physiological data such as skin-conductance, heart-rate variability, pupil dilation, and with established measures of pain such as Numeric rating scale (NRS), Visual analog scale (VAS), general Labeled Magnitude Scale (gLMS). In addition, the investigators study the test-retest reliability of our measure of pain and its ability to capture a reduction in experienced pain due to a topical analgesic product compared to a placebo treatment.

Eligibility Criteria:
Inclusion Criteria:

* age 18-60 years.
* ability and willingness to participate in the study
* declaration of consent
* good English language skills (to ensure understanding of all instructions and the declaration of consent).

Exclusion Criteria:

* inability to give the declaration of consent (e.g. due to linguistic difficulties understanding the study information)
* any neurological disorders
* reduced general health / chronic diseases (e.g. autoimmune disease, severe cardiovascular diseases, insulin-dependent diabetes, severe depression); chronic pain disorders
* pregnancy
* in the week before the experimental session self-reported intake of drugs which could influence pain perception (e.g. cannabis and ADHD medications).
Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation

Complete pelvic and para-aortic lymphadenectomy performed at the time of primary surgical staging for endometrial cancer increases operative time and surgical morbidity, but appears to be necessary in most high grade and deeply invasive cancers. To date, the Mayo Clinic approach has not been reproduced, and the investigators propose to validate their algorithm at the University of Kentucky utilizing intra-operative consultation (IOC). The preliminary data at the University of Kentucky for IOC and endometrial cancer outcomes suggest that the investigators are well-suited to perform this investigation. A surgical approach that is tailored to the patient's cancer biology is rational, supported by the recent literature, and medically compelling since the co-morbidities of many obese, low-risk EC patients put them at significantly increased perioperative risk for complete lymphadenectomy.


Eligibility Criteria:
Inclusion Criteria:

* All patients must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy.
* Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation.
* Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI, or ultrasound. Preoperative imaging is not mandatory for study enrollment.
* Patients may have received prior systemic chemotherapy. Such therapy must have been completed at least 5 years prior to study entry and the patient has no evidence of disease subsequent to such therapy. Patients must not have received neoadjuvant chemotherapy for the present disease.
* Patients must have GOG performance status 0, 1, or 2.
* Patients must have an estimated survival greater than or equal to 3 months
* Patients must have signed an approved informed consent and HIPAA authorization.

Exclusion Criteria:

* Patients with clinical evidence of disease beyond the uterus, including presence of suspicious aortic or inguinal nodes on imaging or clinical exam.
* Patients who have received previous vaginal, pelvic, or abdominal irradiation.
* Patients who received chemotherapy directed at the present disease.
* Patients who have circumstances that will not permit completion of this study or the required follow-up.
* Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of surgical lymph node assessments.
* Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years.
* Patients with GOG Performance Grade of 3 or 4.
Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Neuropathic Pain

A retrospective, monocentric, observational, descriptive, open study of a cohort of 149 patients from January 2014 to December 2015

Neuropathic pain is a public health problem because of its prevalence reaching nearly 7% of the general population and the effectiveness of current treatments often remains incomplete: only 30-40% of patients are relieved of 50% of their pain by a pharmacological approach.

As early as the 1990s, stimulation of the motor cortex by implanted electrodes made it possible to successfully treat certain chronic refractory neuropathic pain. In 1995 it was reported that the application of repeated shocks by transcranial magnetic stimulation of the motor cortex could induce an analgesic effect in a patient suffering from neuropathic pain.

This technique has proved its analgesic efficacy after an induction treatment over 5 days, in the context of chronic pain (neuropathic or fibromyalgia), but all the patients are not responders and there is currently, Of predictive criteria for response. It seems important to continue studies on this non-medicinal, non-invasive therapy with no significant adverse effects.

Eligibility Criteria:
Inclusion Criteria:

- patient older than 18 years old with chronic neuropathic pain who are resistant to drug therapy for which treatment with rTMS is indicated between January 2014 and December 2015

Exclusion Criteria:

* Patient less than 18 years old
* Pregnant woman
* Non-neuropathic pain
* Pain \<6 months
* Unbalanced epilepsy
* Patient with a contraindication for cerebral MRI (cochlear implant, ocular metallic foreign bodies, patient with a pacemaker, mechanical valve)
* Psychiatric pathology
* Person subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty
The Effect of Hydrotherapy and Land-based Rehabilitation Program Combined With Ankle Taping in Athletes With Chronic Ankle Instability

There will be a difference in ankle functional ability between athletes with chronic ankle instability in the intervention group and in the control group.


Eligibility Criteria:
Inclusion Criteria:

* recurrent ankle sprain in one year
* sustain at least one repeated injury or have the experience of ankle instability feelings or "giving way"
* not undergoing formal or informal rehabilitation for the unstable ankle in the last three months
* have residual symptoms after recurrent sprain of the ankle

Exclusion Criteria:

* have the history of fracture or surgical procedures in the lower extremity
* have the history of neurological disorders affecting the lower extremities vestibular dysfunction or balance disorder
* allergic to the zinc oxide compound in the adhesive tape
Peroral Endoscopic Myotomy for the Treatment of Achalasia

There will be a retrospective chart review for patients who underwent endoscopic procedures and POEM from 06/2016 - 01/2019 \& a prospective chart review will be performed for patients who will undergo endoscopic procedures and POEM from 02/2019 - 06/2021

Subjects will undergo no additional tests and procedures as part of this study. All data will be collected from patient's electronic health records (EHR) of the hospital In addition; a prospective chart review will be performed for patients who will undergo endoscopic procedures and POEM from 02/2019 - 06/2021. All the subjects enrolled in prospective chart review will be first consented for their study participation. Subjects will undergo a clinically indicated endoscopic procedure and POEM and subsequent follow-up clinical visits as part of their standard medical care. All procedures, barring research activities such as consenting and data collection from Electronic Health Records, will be either clinically indicated and/or standard of care.

* Each patient in the study will be assigned a Case ID number to de-identify their personal health information during data collection
* The Case ID number connecting the patient to the personal health information will be in an encrypted electronic file on a computer that can only be accessed by study members at MDMC.
* A procedure report and outpatient clinical records for each subject's POEM procedure will be used to record each patient's data for the registry
* That data will only be shared by members of the study (PIs, research coordinator) who require it for conducting of data collection/interpretation

"Disclaimer: Any cost associated with the procedures stated herein will be billed directly to you or to your insurance (as applicable)."

Eligibility Criteria:
Inclusion Criteria:

* Any discharged patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia from 6/2016 to 6/2021.
* Above or equal to 18 years of age

Exclusion Criteria:

* Any patient who has not undergone POEM for the treatment of Achalasia.
* Below 18 years of age
Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer

To assess the potential usefulness of radiogenomics for tumor driving genes heterogeneity in non-small cell lung cancer.

Patients with advanced NSCLC underwent 18F-FDG PET/CT and PET/CT-guided synchronous targeted biopsy of primary and distant metastatic tumors. The LIFEx package was used to extract PET and CT radiomic features from primary and metastatic lesions. The radiomic ROI sites of primary and distant metastatic tumors were point-to-point corresponding to the PET/ CT-guided targeted biopsy sites. Whole exon sequencing of primary and distant metastatic tumor samples obtained by PET/CT-guided targeted biopsy was used to get genomic data of primary and distant metastatic tumor. Predictive radiogenomics models were established and validation.

Eligibility Criteria:
Criteria: Inclusion Criteria:

* (i) adult patients (aged 18 years or order);
* (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);
* (iii) patients who had scheduled both 18F-FDG PET/CT scans and PET/CT guided biopsy;
* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* (i) patients with non-malignant lesions;
* (ii) patients with pregnancy;
* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.


Eligibility Criteria:
Key Inclusion Criteria:

* Established diagnosis of ulcerative colitis (UC) for ≥6 months

  * 20 cm active disease at Screening endoscopy
* Must have active UC with a Mayo Score/Disease Activity Index (DAI) of 6 to 13 points and moderate to severe disease on endoscopy (Mayo endoscopic score of at least 2) despite prior or concomitant treatment
* Colonoscopy within past 5 years for extent of disease and to exclude polyps
* For subjects with UC for more than 10 years, colonoscopy with appropriate biopsies within 1 year prior to Screening to exclude dysplasia and neoplasia.
* Must be willing and able to practice effective birth control during the study and for 1 month after the last dose of study treatment.

Key Exclusion Criteria:

* Diagnosis of indeterminate colitis or Crohn's disease
* Need for imminent surgery
* Diagnosis of primary sclerosing cholangitis or toxic megacolon
* Hemoglobin ≤9 g/dL
* White blood cell count \< 3500 cells/mm\^3
* Lymphocyte count \<1000 cells/µL
* Platelet count \<100,000 cells/µL
* Female subjects who are pregnant or who wish to become pregnant during the study, or who are lactating
* Known symptomatic colonic stricture
* Stool cultures positive for enteric infection
* History of malignant disease
* History of major abdominal surgery (e.g., gastrectomy) within past 5 years
* History of small bowel or colonic obstruction or resection
* History of drug or alcohol abuse (as defined by the Investigator) within 2 years prior to Screening
* Use of anti-diarrheal agents during the screening period
* Previous participation in this study
* Previous treatment with interferon beta or other interferon products

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Determinants of Thyroid Surgery Outcomes

In a large prospective cross-sectional study, the investigators aimed to identify the determinants of thyroid surgery outcomes and quantify the relative influence of preoperative and intraoperative factors. For this purpose, the investigators considered the interplay of several characteristics specific to surgeons, patients, and surgical procedures.


Eligibility Criteria:
Inclusion Criteria:

- All patients who underwent a thyroid procedure between April 2008 and July 2008.

Exclusion Criteria:

- Participation refusal